Albutein 20%
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Decompensated Cirrhosis and Ascites
Conditions
Decompensated Cirrhosis and Ascites
Trial Timeline
Jul 24, 2018 → May 21, 2024
NCT ID
NCT03451292About Albutein 20%
Albutein 20% is a phase 3 stage product being developed by Grifols for Decompensated Cirrhosis and Ascites. The current trial status is completed. This product is registered under clinical trial identifier NCT03451292. Target conditions include Decompensated Cirrhosis and Ascites.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03451292 | Phase 3 | Completed |
Competing Products
5 competing products in Decompensated Cirrhosis and Ascites
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| Mesenchymal Stem Cell | Rohto Pharmaceutical | Pre-clinical | 23 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1/2 | 41 |
| Aliskiren + Placebo | Novartis | Phase 3 | 77 |
| BMS-986259 | Bristol Myers Squibb | Phase 2 | 51 |